- ANVS, a clinical-stage biotech, develops novel treatments addressing Alzheimer's Disease (AD), Parkinson's Disease (PD) and other neurodegenerative diseases.
- ANVS believes that their lead candidate, ANVS401, can inhibit more than one neurotoxic protein, and thereby improve axonal transport and nerve cell health.
- ANVS401 has been shown previously to lower three neurotoxic proteins of Mild Cognitive Impaired patients to the levels seen in healthy volunteers.
- ANVS has two ongoing double-blind, placebo-controlled phase 2a trials: one in AD patients and one in both AD and PD patients, with preliminary data expected in Q1, 2021.
- In this article, I discuss why I think ANVS is a BUY for any investor who has the right risk tolerance for speculative biotech stocks.
For further details see:
Annovis Bio: A Speculative Buy For Their Novel Alzheimer's Disease Treatment